phagemid


Also found in: Wikipedia.

phagemid

An engineered bacteriophage (cloning vector) derived from a phage and a plasmid, into which foreign single- or double-stranded DNA is inserted to facilitate characterisation of cloned inserts of DNA by allowing it to replicate.
 
Applications
High-resolution restriction mapping, rescue of single-stranded DNA, RNA transcription, sequencing of single- and double-stranded nucleic acids, generation of nested deletions, site-directed mutagenesis, prokaryotic expression, eukaryotic expression.
References in periodicals archive ?
pIII fusion phagemid for construction of peptide library;
The pBSK phagemid vector was linearized by EcoRV (Medox Biotech, India) in order to generate termini GATATC.
OSLO, Norway, April 2 /PRNewswire/ -- The human antibody company, Affitech AS announced today that the European Patent Office has granted an European patent on the use of phagemid particles having an antibody-coliphage pIII fusion protein, to identify tumor associated antigens on cells by negative selection.
The human antibody company, Affitech AS (Oslo, Norway) announced that the European Patent Office has granted an European patent on the use of phagemid particles having an antibody-coliphage pIII fusion protein, to identify tumor associated antigens on cells by negative selection.
A hemocyte phagemid unidirectional cDNA library, constructed in the ZAP Expression vector following the manufacturer's recommendations (Stratagene, La Jolla, CA), was previously reported (Jimenez-Vega & Vargas-Albores 2005).
Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induces targeted G.
H] gene fragments were cloned as SfiI cassettes upstream of the coding region for the gIII minor phage coat protein contained in the pAK100 phagemid display vector.
Affitech is the exclusive worldwide patent holder of the phagemid system of antibody and antibody fragments.
The agreement tasks Affitech with first using their proprietary phagemid library, high throughput screening technology and antibody engineering platforms to identify candidate antibodies which Roche would then utilize for further development and commercialization.
Martin Welschof, CEO of Affitech, also commented: "Affitech has developed a fully integrated antibody discovery platform consisting of human antibody libraries with high functionality, based on phagemid display technology plus several screening technologies with high degree of versatility.
The reverse transcription-PCR product was cloned as a SfiI-Not1 fragment into the pCANTAB6 phagemid vector, which produced a myc tag fused to the COOH terminus of the scFv gene.
Under their protocol, the fractionated DNA was packaged into a phagemid or phage vector and an ssDNA library was obtained.